nt13

NT 13 is a partial N-methyl-D-aspartate receptor (NMDAR) agonist used in the study of depression, anxiety, and other related diseases.

(2E)-3-(3,5-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one is also known as DMPVP.It is a novel synthetic compound belonging to the class of cathinones that is psychoactive.

Antiproliferative agent-13 is a compound with antiproliferative activity.

Antimalarial agent 13 (N2-(3-chlorophenyl)-N4-(furan-2-ylmethyl)quinazoline-2,4-diamine) is a potent antimalarial agent.

NT 13 acetate is a partial agonist of NMDA receptor and can be used for research on depression, anxiety, and other related diseases.

Antibiofilm agent-13 (compound 14b) is an effective broad-spectrum antibacterial agent that functions by disrupting the integrity of bacterial cell membranes. It achieves this through the degradation of transmembrane potential and increased membrane permeability, which leads to the production of intracellular ROS and the leakage of DNA and proteins, ultimately resulting in bacterial death. Antibiofilm agent-13 effectively inhibits both Gram-positive bacteria (MIC ranging from 0.5-1 μg/mL) and Gram-negative bacteria (MIC ranging from 1-32 μg/mL).

Antituberculosis agent-13 (Compound 11) demonstrates antituberculosis activity, effectively inhibiting both wild-type and mutant strains of Mycobacterium tuberculosis, with an IC50 range of 4-62.5 nM. Additionally, Antituberculosis agent-13 exhibits anti-leukemia properties, inhibiting MOLM-13 with an IC50 of 3.8 μM.

Antifungalagent 131 (compound A20) is an antifungal agent with a minimum inhibitory concentration (MIC) of 64 μg/mL. When used in combination with Fluconazole, it demonstrates exceptional antifungal potential.

Antifungalagent 132 (compound 25) is a selective and potent antifungal agent. It inhibits Cryptococcus neoformans May1 with a Ki value of 180 pM.

Antifungalagent 130 (Compound A7) is an orally active antifungal agent exhibiting significant inhibitory activity against Candida glabrata [MIC= 0.12 ng/mL] and Cryptococcus neoformans [MIC= 0.12 ng/mL]. It effectively disrupts fungal cell iron homeostasis and induces oxidative stress, leading to antifungal effects. Additionally, Antifungalagent 130 inhibits the formation of fungal virulence factors, such as biofilms, capsules, urease, and melanin. This compound shows strong antifungal properties, making it suitable for research on drug-resistant fungal infections.

Antitumor agent-133 (compound 4d) is a bis-santine derivative that demonstrates activity against Huh1 (IC50 = 17.13 μM) and Huh7 (IC50 = 8.27 μM). It induces autophagy and inhibits tumor growth by modulating the levels of the LC3BII, ATG5, and p62 proteins.

Antitumor agent-135 (Compound 13) is an effective anticancer drug that induces apoptosis. It exhibits IC50 values of 3.79, 10.55, 1.14, and 4.14 μM against NSCLC cell lines (A549, H460, PC-9, and PC-9/GR), respectively.

Antitumor agent-132 (Compound F9) is a compound with antitumor properties. It induces apoptosis, increases intracellular ROS, and decreases MMP.

Antitumor agent-139 (compound 9b) is a gold (I) complex targeting liver and mitochondria, capable of generating reactive oxygen species (ROS) and facilitating DNA excretion. It inhibits tumor growth in patient-derived liver cancer xenograft models.

Anti-MRSA agent 13 (Compound 9b) is an effective antimicrobial against methicillin-resistant Staphylococcus aureus (MRSA) with a minimal inhibitory concentration (MIC) of 0.5–2 μg/mL for clinically isolated strains. It exhibits excellent biocompatibility, stable plasma tolerance, and a low propensity for resistance. Anti-MRSA agent 13 disrupts the cell wall and membrane, reduces metabolic activity, induces oxidative damage, and impairs DNA function, leading to MRSA death through a multi-target synergistic mechanism.

Antifungalagent 134 (Compound B13) is an antifungal agent effective against Botrytis cinerea, Alternaria solani, Fusarium graminearum, Rhizoctonia solani, Colletotrichum orbiculare, and Alternaria alternata with EC50 values of 3.24, 1.89, 1.70, 0.36, 4.27, and 1.50 μg/mL, respectively. It disrupts the fungal cell membranes and mitochondria, leading to substantial accumulation of reactive oxygen species (ROS). Additionally, Antifungalagent 134 exhibits significant herbicidal activity on field weeds such as Amaranthus retroflexus L and Abutilon theophrasti Medicus, and is applicable in crop disease and field weed research.

Antifungalagent 133 (compound D2) is an orally active antifungal compound with an MIC80 value of 0.13 µg/mL against C. neoformans H99. It is suitable for research on cryptococcal meningitis.

Anticancer agent 13 is a compound derived from dicarboxylic acids and amines, developed for use as an anticancer agent.

Antitubercular agent-13 (Compound 3d) is an antitubercular compound with MIC values of 0.007 μg/mL against MTB H37Rv and 1.851 μg/mL against MDR-MTB 16833, respectively, and exhibits metabolic instability [1].

Antifungal agent 13 demonstrates significant antifungal activity against Sclerotinia sclerotiorum, achieving an EC50 of 1.25 mg/L.

Anti-inflammatory agent 13 is a pentacyclic triterpene compound with a significant inhibitory effect on inflammation models. anti-inflammatory agent 13 has the potential to be used in studies of DAMP or PAMP-induced inflammation.

AMG-131 besylate is a hypoglycemic agent. It is a potent PPARγ partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.

Antileishmanial agent-13, a quinoline-isatin hybrid, functions as an antileishmanial agent targeting the L. Major Leishmania strain through an anti-folate mechanism. This compound exhibits potent inhibition of both the promastigote and amastigote forms, boasting IC50 values of 0.604 μM and 0.508 μM, respectively.

Antibacterial agent 131 is a compound with antibacterial properties.